deltatrials
Terminated PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT03167151

Pembrolizumab in Intermediate Risk Recurrent Non-muscle Invasive Bladder Cancer (NMIBC) (PemBla)

A Parallel Group Phase I/II Marker Lesion Study to Assess the Safety, Tolerability and Efficacy of Intravenous or Intravesical Pembrolizumab in Intermediate Risk Recurrent Non-muscle Invasive Bladder Cancer

Sponsor: Merck Sharp & Dohme LLC

Conditions Non-muscle Invasive Bladder Cancer (NMIBC)
Interventions Pembrolizumab
Updated 11 times since 2017 Last updated: Jul 15, 2020 Started: Mar 2, 2018 Primary completion: Mar 26, 2019 Completion: Jun 26, 2019
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

The study failed to recruit within the permitted timeframe

Other terminated trials from Merck Sharp & Dohme LLC

More terminations from Merck Sharp & Dohme LLC

This PHASE1/PHASE2 trial investigates Non-muscle Invasive Bladder Cancer (NMIBC) and is currently terminated or withdrawn. Merck Sharp & Dohme LLC leads this study, which shows 11 recorded versions since 2018 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jun 2017 – ~Aug 2017 · 2 months · monthly snapshotNot Yet Recruiting~Aug 2017 – ~Jun 2018 · 10 months · monthly snapshotRecruiting~Jun 2018 – ~Dec 2018 · 6 months · monthly snapshotRecruiting~Dec 2018 – ~Aug 2020 · 20 months · monthly snapshotRecruiting~Aug 2020 – ~Nov 2020 · 3 months · monthly snapshotTerminated~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshotTerminated~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshotTerminated~Dec 2021 – ~Jun 2022 · 6 months · monthly snapshotTerminated~Jun 2022 – ~Jul 2024 · 25 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – present · 24 months · monthly snapshotTerminated

Change History

11 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. Jun 2022 — Jul 2024 [monthly]

    Terminated PHASE1_PHASE2

  4. Dec 2021 — Jun 2022 [monthly]

    Terminated PHASE1_PHASE2

  5. Jan 2021 — Dec 2021 [monthly]

    Terminated PHASE1_PHASE2

▶ Show 6 earlier versions

  1. Nov 2020 — Jan 2021 [monthly]

    Terminated PHASE1_PHASE2

  2. Aug 2020 — Nov 2020 [monthly]

    Terminated PHASE1_PHASE2

    Status: Recruiting → Terminated

  3. Dec 2018 — Aug 2020 [monthly]

    Recruiting PHASE1_PHASE2

  4. Jun 2018 — Dec 2018 [monthly]

    Recruiting PHASE1_PHASE2

  5. Aug 2017 — Jun 2018 [monthly]

    Recruiting PHASE1_PHASE2

    Status: Not Yet Recruiting → Recruiting

  6. Jun 2017 — Aug 2017 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Merck Sharp & Dohme LLC
  • University of Oxford
Data source: University of Oxford

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations